Home >> Tag Archives: Myriad Genetics—

Tag Archives: Myriad Genetics—

BRACAnalysis CDx approved as Talzena companion dx

Oct. 22, 2018—Myriad Genetics announced that the FDA has approved its BRACAnalysis CDx to identify patients with HER2-negative metastatic breast cancer who have a germline BRCA mutation and are eligible for treatment with Pfizer’s PARP inhibitor, Talzena (talazoparib). Talzena is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast ...

Read More »

Myriad Genetics to acquire Counsyl

June 4, 2018—Myriad Genetics has signed a definitive agreement to acquire Counsyl for $375 million in cash and stock. Counsyl, founded in 2007, has generated more than $134 million in revenue in the past 12 months and performed more than 280,000 reproductive genetic tests. “By offering Counsyl’s best-in-class reproductive testing products in conjunction with Myriad’s leading hereditary cancer tests, we ...

Read More »

FDA approves Myriad test as a CDx for Lynparza

Jan. 17, 2018—Myriad Genetics announced that the FDA approved BRACAnalysis CDx for use as a companion diagnostic to identify patients with HER2-negative metastatic breast cancer who have a germline BRCA mutation and are candidates for treatment with the PARP inhibitor Lynparza (olaparib), marketed by AstraZeneca and Merck. BRACAnalysis CDx is the first FDA-approved test for use in this indication. “This ...

Read More »

Myriad launches EndoPredict, 7/17

July 2017—Myriad Genetics has launched the EndoPredict test in the U.S. for patients with ER+ HER2- early stage breast cancer. EndoPredict is a second-generation test for assessing the 10-year risk of disease recurrence following surgery and for determining which patients can safely forgo adjuvant chemotherapy.

Read More »

Network taps Myriad for hereditary cancer testing

Oct. 7, 2016—The US Oncology Network has selected Myriad Genetic Laboratories as its preferred provider laboratory for hereditary cancer testing. The US Oncology Network is one of the nation’s largest networks of integrated, community-based, and independent physician practices, with more than 1,000 affiliated physicians in 19 states. As part of the collaboration, Myriad and the US Oncology Network will work ...

Read More »

Myriad to acquire Assurex Health

Aug. 24, 2016—Myriad Genetics has signed a definitive agreement to acquire Assurex Health, which offers genetic testing for psychotropic medicine selection, for $225 million up front with the potential for $185 million in additional performance-based milestones. Assurex generated revenue of more than $60 million and tested more than 150,000 patients in Myriad’s fiscal year 2016. “Assurex provides Myriad access to ...

Read More »

myChoice HRD increases eligible patients, 8/16

August 2016—Myriad Genetics announced that its myChoice HRD test successfully identified an increased number of patients with ovarian cancer who may benefit from treatment with niraparib, an investigational oral PARP inhibitor being developed by Tesaro. The announcement follows results of the NOVA study, which evaluated the safety and efficacy of niraparib as a maintenance therapy in more than 500 patients with recurrent ovarian cancer.

Read More »